Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
18,656,839
-
Share change
-
+8,289,820
-
Total reported value
-
$183,366,118
-
Price per share
-
$10.03
-
Number of holders
-
29
-
Value change
-
+$81,713,433
-
Number of buys
-
16
-
Number of sells
-
7
Institutional Holders of Silence Therapeutics plc - ADS (SLN) as of Q3 2022
As of 30 Sep 2022,
Silence Therapeutics plc - ADS (SLN) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,656,839 shares.
The largest 10 holders included
Lombard Odier Asset Management (USA) Corp, Lombard Odier Asset Management (Europe) Ltd, TCG Crossover Management, LLC, Deep Track Capital, LP, BVF INC/IL, Aquilo Capital Management, LLC, Frazier Life Sciences Management, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., GOLDMAN SACHS GROUP INC, and AXA S.A..
This page lists
29
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.